secwatch.observer — SEC 8-K summary
======================================

Issuer:     GYRE THERAPEUTICS, INC. (GYRE)
CIK:        0001124105
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0000950170-24-056893
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gyre Therapeutics Q1 2024 revenue $27.2M, net income $9.9M; F351 Phase3 data due early 2025
--------------------------------------------------------------------------------

- Revenue $27.2M (+9% YoY); net income $9.9M vs $4.2M; ETUARY sales $26.9M (+10% YoY).
- Cash $29.8M as of March 31, 2024 (from $33.5M at Dec 2023); expects >12 months runway.
- Phase 3 F351 for CHB liver fibrosis on track; topline data expected by early 2025.
- U.S. IND for F351 in NASH fibrosis expected late 2024; Phase 2a trial planned in 2025.
- Acquired nintedanib rights from Jiangsu Wangao to strengthen PRC pulmonary fibrosis franchise.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124105/000095017024056893/0000950170-24-056893-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124105/000095017024056893/gyre-20240509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-056893

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer